| Literature DB >> 29267186 |
Huai Xiao1,2,3, Jian-Wei Dong4, Di-Jiao Zhou5, Xiu-Mei Wu6,7, Jian-Rong Luo8, Cheng-Gui Zhang9,10, Na-Na Guo11,12, Yue Li13,14, Le Cai15, Zhong-Tao Ding16.
Abstract
Blaps rynchopetera Fairmaire has long been used as a folk medicine by the Yi and Bai ethnic groups in China to treat fever, cough, gastritis, boils, and tumors. In the present study, the cytotoxicity of the defensive secretion (TDS) of B. rynchopetera against AGS Caco-2, HepG2 U251 and Bel-7402 was tested, and the results revealed that TDS had potent cytotoxicity against testing cells with IC50 values of 45.8, 17.4, 53.6, 98.4 and 23.4 μg/mL, respectively. Gas chromatography-mass spectrometry (GC-MS) analysis was employed to clarify the cytotoxic constituents in TDS of B. rynchopetera and five volatile compounds, including 2-ethyl-2,5-cyclohexadiene-1,4-dione (3, 31.00%), 1-tridecene (5, 28.02%), 2-methyl-2,5-cyclohexadiene-1,4-dione (2, 22.86%), hydroquinone (4, 1.33%), and p-benzoquinone (1, 1.01%), were identified. Chemical constituent investigation on TDS further supported the presence of 5 above compounds. A cytotoxic assay indicated that compounds 1, 2, 3 and 4 exhibited significant cytotoxicity against the testing cell lines, implying that benzoquinones and hydroquinone played important roles in the cytotoxicity of TDS of B. rynchopetera. TDS is a cytotoxic natural material and further studies investigating mechanisms and inhibitory activities on other cell lines is warranted.Entities:
Keywords: Blaps rynchopetera Fairmaire; benzoquinones; cytotoxicity; hydroquinone; the defensive secretion
Mesh:
Substances:
Year: 2017 PMID: 29267186 PMCID: PMC5943921 DOI: 10.3390/molecules23010010
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1–5.
IC50 inhibition of TDS and its main constituents against human cancer cell lines.
| Compounds | IC50 (μg/mL)/[± Standard Deviation, | ||||
|---|---|---|---|---|---|
| AGS | Caco-2 | HepG2 | U251 | Bel-7402 | |
| 2.2 ± 0.3 | 1.6 ± 0.3 | 2.0 ±0.2 | 1.0 ± 0.1 | 1.7 ± 0.1 | |
| mitoxantrone (MA) | 2.0 ± 0.2 | 2.6 ± 0.3 | 7.7 ± 0.3 | 0.9 ± 0.1 | 5.8 ± 0.9 |
| defensive secretion | 45.8 ± 5.9 | 17.4 ± 2.0 | 53.6 ± 5.6 | 98.4 ± 4.8 | 23.4 ± 1.2 |
| 12.8 ± 1.1 | 10.2 ± 1.3 | 23.1 ± 4.2 | 36.5 ± 5.4 | 11.6 ± 0.9 | |
| mixture of | 3.6 ± 0.6 | 2.8 ± 0.5 | 3.8 ± 0.4 | 3.7 ± 0.8 | 2.8 ± 0.2 |
| 23.9 ± 0.9 | 10.8 ± 0.5 | 33.5 ± 2.1 | 44.2 ± 3.9 | 16.1 ± 0.8 | |
Figure 2Inhibitory rate curves of TDS on tumor cell lines.
Figure 3Total ion current chromatogram of TDS (A) and the volatile extract of whole body powder (B).
Possible components in the defensive secretion of B. rynchopetera.
| No. | Retention Time (min) | Content (%) | Compound | Molecular Formula | Molecular Weight | Similarity |
|---|---|---|---|---|---|---|
| 1 | 3.302 | 1.01 | C6H4O2 | 108 | 95 | |
| 2 | 4.684 | 22.86 | 2-methyl-2,5-cyclohexadiene-1,4-dione | C7H6O2 | 122 | 97 |
| 3 | 5.161 | 3.51 | Not identified | |||
| 4 | 6.484 | 31.00 | 2-ethyl-2,5-cyclohexadiene-1,4-dione | C8H8O2 | 136 | 93 |
| 5 | 10.394 | 1.33 | Hydroquinone | C6H6O2 | 110 | 92 |
| 6 | 10.943 | 28.02 | 1-tridecene | C13H26 | 182 | 98 |
| 7–15 | 12.27 | Not identified | ||||
| Total | 100.00 | |||||
| Total identified | 84.22 | |||||
Figure 4Inhibition of main compounds from TDS for testing cell lines: (A) Compound 1; (B) Mixture of 2 and 3; (C) compound 4.